← Every company
Sarepta Therapeutics Inc Patents
What Sarepta Therapeutics Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
SRPT on carbonthat →Filings on file
51
Granted
1
Still pending
50
Filed under
2 names
51 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| SUSPENSION MODE SEED TRAIN DEVELOPMENT FOR ADHERENT CELLSC12N 5/0037, C12N 7/00, C12N 5/0686, C12N 15/86, C12N2500/90, C12N2750/14143, C12N2750/14152Filed as Sarepta Therapeutics, Inc.2026-02-12Maroof ALAM | pending |
| FUSION PROTEINS COMPRISING CAS ENZYMES AND DNA-BINDING PROTEINSC12N 9/226, C12N 9/22, C12N2310/20, A61K 38/465, C07K 14/001, C07K2319/09, C07K2319/80, C07K2319/81, C12N 15/11, C12N 15/113, C12N 15/85, C12Y 301/21004Filed as SAREPTA THERAPEUTICS, INC.2025-11-14Eric WALTON | pending |
| ANTISENSE OLIGOMERS FOR TREATMENT OF CHRONIC KIDNEY DISEASEC12N 15/113, A61K 47/64, A61P 13/12, A61K 31/7105, C12N2310/11, C12N2310/14, C12N2310/3233, C12N2310/3513Filed as SAREPTA THERAPEUTICS, INC.2025-10-27Ryan OLIVER | pending |
| DYSTROPHIN AND MICRO-DYSTROPHIN ANTIBODIES AND FRAGMENTS THEREOFFiled as SAREPTA THERAPEUTICS, INC.2025-09-30WENJING XU | pending |
| DEFICIENT CAS-TRANSCRIPTIONAL REPRESSOR FUSIONS FOR REGULATION OF GENE EXPRESSIONFiled as SAREPTA THERAPEUTICS, INC.2025-08-15CHARIS L. HIMEDA | pending |
| RAAV PRODUCTION METHODSFiled as SAREPTA THERAPEUTICS, INC.2025-07-28Stephen ZANO | pending |
| METHODS FOR TREATING MUSCULAR DYSTROPHYA61K 31/7125, C12N 15/113, A61P 21/00, A61K 9/0019, A61K 47/02, C12N2310/11, C12N2310/3145, C12N2310/3233, C12N2320/33, C12N2320/35Filed as Sarepta Therapeutics, Inc.2025-06-27Gilmore O'NEILL | pending |
| MUSCLE TROPIC RAAVC12N 15/86, A61P 21/00, A61K 38/00, A61K 38/1719, A61K 47/02, A61K 47/10, A61K 47/18, A61K 47/26, A61K 48/005, A61K 48/0058, C07K 14/005, C07K 14/4708, C07K 14/4716, C12N2750/14122, C12N2750/14143, C12N2750/14145, C12N2810/40, C12N2830/008, C12N2830/42, C12N2830/50Filed as Sarepta Therapeutics, Inc.2025-05-30John SNEDEKER | pending |
| MUSCLE TROPIC RAAVFiled as SAREPTA THERAPEUTICS, INC.2025-05-30ARANI CHANDA | pending |
| TREATMENT OF GENETIC NEUROLOGICAL CONDITIONS WITH GENOMIC EDITINGA61K 48/0058, C12N 15/113, C12N2310/20, C12N 9/226, C12N 15/11, C12N 15/86, C12N2750/14143Filed as Sarepta Therapeutics, Inc.2025-04-23Ami M. KABADI | pending |
| TREATMENT OF GENETIC NEUROLOGICAL CONDITIONS WITH GENOMIC EDITINGFiled as SAREPTA THERAPEUTICS, INC.2025-04-23AMI M. KABADI | pending |
| GENETIC CONSTRUCTS FOR GENE EDITINGFiled as SAREPTA THERAPEUTICS, INC.2025-04-17AMI M. KABADI | pending |
| GENETIC CONSTRUCTS FOR GENE EDITINGA61K 48/005, C12N 15/86, C12N2310/20, A61P 21/00, C12N 9/226, A61K 9/0019, A61K 38/1719, A61K 48/0075, C07K 14/4707, C07K 14/4708, C07K 14/471, C12N 9/22, C12N 15/111, C12N 15/113, C12N 15/907, C12N2320/11, C12N2750/14143, C12N2830/205Filed as Sarepta Therapeutics, Inc.2025-04-17Ami M. KABADI | pending |
| ANTISENSE OLIGOMER COMPOUNDSA61K 47/6455, C12N 15/113, C12N 15/111, C12N2310/11, C12N2310/3233, C12N2310/3513, C12N2320/33, C12N2320/50Filed as Sarepta Therapeutics, Inc.2025-03-21Frederick J. SCHNELL | pending |
| POMPE DISEASE MOUSE MODEL GENERATION, CHARACTERIZATION AND METHODS OF USEA01K 67/0278, C12N2310/20, C12N 9/226, A01K2207/15, A01K2217/072, A01K2227/105, A01K2267/0306, C12N 9/2408, C12N 9/2465, C12N 15/1096, C12N 15/111, C12N 15/113, C12N 15/8509, C12N2015/8527, C12N2310/11, C12N2830/50, C12Q 1/6806, C12Q 1/686, C12Q 1/6883, C12Y 302/0102, G01N 33/573, G01N2333/924Filed as Sarepta Therapeutics, Inc.2025-03-21Ryan OLIVER | pending |
| RECOMBINANT AAV VECTORS FOR TREATING MUSCULAR DYSTROPHYA61K 48/005, C07K 14/4708, C12N 15/86, A61P 21/00, A61K 38/00, A61K 48/0058, A61K 48/0075, A61K 48/0083, C07K 14/4716, C12N 5/0018, C12N 5/0686, C12N 7/00, C12N2500/84, C12N2527/00, C12N2710/10322, C12N2750/14143, C12N2750/14151, C12N2750/14152, C12N2800/22, C12N2800/40, C12N2830/008, C12Q 1/6883, C12Q2600/106, G01N2800/52Filed as Sarepta Therapeutics, Inc.2025-03-21Louise RODINO-KLAPAC | pending |
| DMD ANTISENSE OLIGONUCLEOTIDE-MEDIATED EXON SKIPPING EFFICIENCYFiled as Sarepta Therapeutics, Inc.2025-03-18Chia-Ling WU | pending |
| HUMANIZED UMOD MOUSE MODEL GENERATION, CHARACTERIZATION AND METHODS OF USEFiled as SAREPTA THERAPEUTICS, INC.2025-03-12RYAN OLIVER | pending |
| EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHYC12N 15/113, C12N2310/11, C12N2310/3145, C12N2310/3233, C12N2310/3513, C12N2320/33Filed as Sarepta Therapeutics, Inc.2025-03-05Frederick Joseph SCHNELL | pending |
| PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERSC07F 9/062, C07F 9/65583, C07F 9/65616Filed as Sarepta Therapeutics, Inc.2025-02-21Baozhong CAI | pending |
| METHODS FOR TREATING MUSCULAR DYSTROPHY WITH CASIMERSENA61K 31/7125, A61K 48/00, A61P 21/00, A61P 21/04, A61P 43/00, A61K 9/0019, A61K 47/26Filed as Sarepta Therapeutics, Inc.2025-02-11Edward M. KAYE | pending |
| PEPTIDE OLIGONUCLEOTIDE CONJUGATESA61K 47/645, A61K 47/64, A61K 38/00, A61P 21/00, A61P 21/04, A61P 31/12, Y02A 50/30, A61P 31/04, A61K 31/7088, A61K 47/18, C07K 7/06, C07K 7/08Filed as Sarepta Therapeutics, Inc.2025-01-17Gunnar J. HANSON | pending |
| METHODS OF TREATING MUSCULAR DYSTROPHYC07K 14/4708, C12N 15/86, A61P 21/00, A61K 35/761, A61K 38/47, A61K 38/4873, A61K 48/005, A61K 48/0058, A61K 48/0083, A61K2300/00, C12N2750/14143, C12N2830/008, C12Y 304/18, G01N 33/6854, G01N2800/2878Filed as Sarepta Therapeutics, Inc.2024-12-17Louise RODINO-KLAPAC | pending |
| COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHYA61K 31/7125, C12N 15/113, A61P 21/00, A61P 21/02, A61P 1/00, A61K 9/0019, C12N2310/33, C12N2320/30Filed as Sarepta Therapeutics, Inc.2024-12-03Edward M. KAYE | pending |
| HUMANIZED DNM2 MOUSE MODEL GENERATION, CHARACTERIZATION AND METHODS OF USEFiled as SAREPTA THERAPEUTICS, INC.2024-10-18RYAN OLIVER | pending |
| ANTISENSE OLIGOMERS FOR TREATMENT OF CENTRONUCLEAR MYOPATHIESFiled as SAREPTA THERAPEUTICS, INC.2024-10-18CRAIG MCINTOSH | pending |
| ANTISENSE OLIGOMERS AND METHODS OF USING THE SAME FOR TREATING DISEASES ASSOCIATED WITH THE ACID ALPHA-GLUCOSIDASE GENEC07H 21/02, C12N 15/113, Y02P 20/582, A61P 43/00, A61P 3/00, A61P 3/10, A61K 9/0019, A61K 9/0053, A61K 31/7105, C07H 21/04, C12N 15/1137, C12N2310/11, C12N2310/31, C12N2310/3145, C12N2310/3233, C12N2310/351, C12N2310/3513, C12N2320/33, C12Y 302/0102Filed as Sarepta Therapeutics, Inc.2024-10-09Frederick Joseph SCHNELL | pending |
| DYSTROPHIN AND MICRO-DYSTROPHIN ANTIBODIES AND FRAGMENTS THEREOFFiled as Sarepta Therapeutics, Inc.2024-10-01Wenjing XU | pending |
| ADAPTED HUMAN DYSTROPHINS WITH ENHANCED ACTIN-BINDING AFFINITY FOR TREATING MUSCULAR DYSTROPHIESFiled as SAREPTA THERAPEUTICS, INC.2024-09-24JAMES ERVASTI | pending |
| METHODS OF RISK ASSESSMENT FOR MUSCULAR DYSTROPHY GENE THERAPYFiled as SAREPTA THERAPEUTICS, INC.2024-09-16SOHRAB KHAN | pending |
| EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHYC12N 15/11, C12N 15/113, A61K 47/6455, A61K 47/60, A61P 21/00, A61P 21/04, A61P 43/00, Y02A 50/30, A61K 31/7088, A61K 31/713, C12N 15/111, C12N2310/11, C12N2310/3233, C12N2310/33, C12N2310/351, C12N2310/3513, C12N2310/3535, C12N2320/30, C12N2320/33Filed as Sarepta Therapeutics, Inc.2024-09-13Richard K. BESTWICK | pending |
| EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHYC12N 15/11, C12N 15/113, A61K 47/6455, A61K 47/60, A61P 21/00, A61P 21/04, A61P 43/00, Y02A 50/30, A61K 31/7088, A61K 31/713, C12N 15/111, C12N2310/11, C12N2310/3233, C12N2310/33, C12N2310/351, C12N2310/3513, C12N2310/3535, C12N2320/30, C12N2320/33Filed as Sarepta Therapeutics, Inc.2024-09-13Richard K. BESTWICK | pending |
| PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER CONJUGATESA61K 47/549, C12N 15/113, A61P 21/04, A61K 31/712, C12N2310/11, C12N2310/14, C12N2310/3233, C12N2310/3519, C12N2320/33Filed as Sarepta Therapeutics, Inc.2024-08-30Gunnar J. HANSON | pending |
| COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHYA61K 31/7125, C12N 15/113, A61P 21/00, A61P 21/02, A61P 1/00, A61K 9/0019, C12N2310/33, C12N2320/30Filed as Sarepta Therapeutics, Inc.2024-08-23Edward M. KAYE | pending |
| MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHYA61K 31/712, A61P 25/14, A61P 21/00, A61K 31/7125, C12N 15/11, C12N2310/3145, C12N2310/3233, C12N2310/33Filed as Sarepta Therapeutics, Inc.2024-08-23Marco A. Passini | pending |
| EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHYA61K 47/6807, A61K 47/645, A61K 31/7088, A61K 47/549, A61P 25/14, A61P 21/00, A61K 48/00, C12N 15/113Filed as Sarepta Therapeutics, Inc.2024-08-16Marco A. PASSINI | pending |
| GENETIC CONSTRUCTS FOR GENE EDITINGFiled as SAREPTA THERAPEUTICS, INC.2024-08-15Ami M. KABADI | pending |
| NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERYFiled as SAREPTA THERAPEUTICS, INC.2024-08-02CHARLOTTE E. FARQUHAR | pending |
| MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMDC12N 15/113, A61P 21/00, A61P 21/04, A61K 48/00, C12N 15/111, C12N2310/11, C12N2310/321, C12N2310/3233, C12N2310/331, C12N2310/3341, C12N2310/3513, C12N2320/30, C12N2320/33Filed as Sarepta Therapeutics, Inc.2024-07-19Peter SAZANI | pending |
| DOSE PACKAGING SYSTEM FOR MEDICATION AND METHOD OF STORING DOSE THEREINA61J 1/1425, B65D 5/48038, A61J 1/03, B65D 5/38, B65D 5/52, B65D 5/5445, B65D 5/6602, B65D 77/042, B65D 77/0426Filed as Sarepta Therapeutics, Inc.2024-06-21Harry Tugurian | 12653756 |
| MUSCLE TROPIC RAAVFiled as Sarepta Therapeutics, Inc.2024-06-17John SNEDEKER | pending |
| EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHYC12N 15/113, A61K 47/6455, A61K 47/6807, A61P 21/00, A61K 31/7088, C07K 7/06, C07K 7/08, C12N2310/11, C12N2310/3233, C12N2310/3513, C12N2310/3515, C12N2320/33Filed as Sarepta Therapeutics, Inc.2024-06-14Frederick Joseph SCHNELL | pending |
| MUSCLE TROPIC RAAVFiled as Sarepta Therapeutics, Inc.2024-05-31John SNEDEKER | pending |
| ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF RETT SYNDROMEC12N 15/86, A61P 25/28, A61K 38/185, A61K 48/005, A61K 48/0058, A61K 48/0066, C07K 14/4702, C07K 14/475, C07K 14/61, C12N2750/14143, C12N2750/14171, C12N2830/008, C12N2830/15, C12N2830/38, C12N2830/50Filed as Sarepta Therapeutics, Inc.2024-05-31Colin O'Banion | pending |
| FUSION PROTEINS COMPRISING CAS ENZYMES AND DNA-BINDING PROTEINSFiled as SAREPTA THERAPEUTICS, INC.2024-05-15ERIC WALTON | pending |
| PEPTIDE OLIGONUCLEOTIDE CONJUGATESA61K 47/64, A61K 47/605, A61K 47/645, A61K 47/549, A61K 47/60Filed as Sarepta Therapeutics, Inc.2024-05-08Gunnar J. Hanson | pending |
| ANTISENSE OLIGOMERS FOR TREATMENT OF CHRONIC KIDNEY DISEASEC12N 15/113, C12N 15/1138, A61K 47/645, A61P 13/12, A61K 31/7125, C12N2310/11, C12N2310/315, C12N2310/3233, C12N2310/3513, C12N2320/33Filed as Sarepta Therapeutics, Inc.2024-04-26Ryan OLIVER | pending |
| ANTISENSE OLIGOMERS FOR TREATMENT OF CHRONIC KIDNEY DISEASEFiled as SAREPTA THERAPEUTICS, INC.2024-04-26RYAN OLIVER | pending |
| TREATMENT OF GENETIC NEUROLOGICAL CONDITIONS WITH GENOMIC EDITINGFiled as SAREPTA THERAPEUTICS, INC.2024-04-24Ami M. KABADI | pending |
| MORPHOLINO OLIGOMERS FOR TREATMENT OF PERIPHERAL MYELIN PROTEIN 22 RELATED DISEASESC12N 15/113, C12N2310/11, C12N2310/321, C12N2310/3233, C12N2310/3513, C12N2320/33Filed as SAREPTA THERAPEUTICS, INC.2024-04-19Stephen Donald WILTON | pending |
| GENETIC CONSTRUCTS FOR GENE EDITINGFiled as SAREPTA THERAPEUTICS, INC.2024-04-18Ami M. KABADI | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on SRPT
Company overviewEverything on SRPT in one place, with the price.SEC filingsWhat SRPT's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat SRPT's own officers and directors buy and sell.Executive payWhat SRPT awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in SRPT.Funds holding itWhich funds and ETFs hold SRPT, and how big a bet.LobbyingWhat SRPT spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on SRPT's account, and who they worked for.